Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
9 September 2024
Australia releases new mandatory guardrails and voluntary standards on AI – what you need to know
1 September 2024
The Unified patent court and unitary patent – An introduction
1 September 2024
How to get a Unitary Patent
1 September 2024
Which states are in the UPC & where will a UP have effect?
16 August 2024
Principles for setting climate targets: A guide for Australian boards
22 July 2024
Australian Competition & Consumer Commission releases draft sustainability collaboration guidance
28 June 2024
Helping Life Sciences companies land and expand globally
6 June 2024
The Australian Government’s “Closing Loopholes” industrial relations reforms: What they mean for your business
20 March 2024
Pharma – Strong year ahead
13 March 2024
Generative AI: A bilateral online safety focus for Australia and the UK
30 August 2023
Ghostbusters: In a New Win for Providers, No Surprises Act Rules Struck for Allowing Ghost Rates
Last week, the federal government met its fourth loss in a challenge brought by health care and air ambulance providers against No Surprises Act (NSA) …
8 August 2023
No Surprises Here: Providers Score Third Victory in No Surprises Act Litigation, Other Challenges to the NSA Continue
Congress enacted the No Surprises Act (NSA) in 2020 to reduce surprise medical bills and to provide a simple and fast procedure for out-of-network health …
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane